Listar por autor "Suardíaz García, Margarita"
Mostrando ítems 1-6 de 6
-
Decreased soluble IFN-β receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker
Órpez-Zafra, Teresa; Pavía-Molina, José
; Hurtado-Guerrero, Isaac; Pinto-Medel, Maria Jesús; Rodríguez-Bada, José Luis; Urbaneja, Patricia; Suardíaz García, Margarita; Villar, Luisa M; Comabella, Manuel; Montalban, Xavier; Alvarez-Cermeño, Jose C; Leyva-Fernández, Laura; Fernández-Fernández, Óscar; Oliver-Martos, Begoña[et al.] (SAGE Journals, 2017)
Background: The soluble isoform of the interferon-β (IFN-β) receptor (sIFNAR2) could modulate the activity of both endogenous and systemically administered IFN-β. Previously, we described lower serum sIFNAR2 levels in ... -
Eficacia de las terapias celular y génica como agentes inmunomoduladores en el tratamiento de la esclerosis múltiple
(Servicio de Publicaciones y Divulgación Científica, 2015)El interferón beta (IFNb) ha sido uno de los fármacos más utilizados en el tratamiento de la esclerosis múltiple (EM), gracias a su efecto inmunomodulador, antiproliferativo y antiviral. Sin embargo, existe un porcentaje ... -
Gene expression in IFNß signalling pathway differs between monocytes, CD4 and CD8 T cells from MS patients
Oliver-Martos, Begoña; Órpez, Teresa; Pinto-Medel, Maria Jesús; Mayorga Mayorga, Cristobalina; García-León, Juan Antonio; Maldonado-Sanchez, Rafael; Suardíaz García, Margarita; Guerrero, Miguel; Luque, Gloria; Leyva-Fernández, Laura; Fernández Fernández, Óscar[et al.] (Elsevier, 2011)
IFNß exerts its activity through the interaction with IFNAR, through activation of the JAK/STAT pathway. We analyzed the changes in IFNAR1, IFNAR2, STAT1, STAT2, Tyk2, JAK1, IRF9 and MxA gene expressions after prolonged ... -
Gene therapy with mesenchymal stem cells expressing IFN-ß ameliorates neuroinflammation in experimental models of multiple sclerosis
Marín Bañasco, Carmen; Benabdellah, K; Melero-Jerez, C; Oliver-Martos, Begoña; Pinto-Medel, Maria Jesús; Hurtado-Guerrero, Isaac; de Castro, Fernando; Clemente, Diego; Fernández-Fernández, Óscar; Martín, F; Leyva-Fernández, Laura; Suardíaz García, Margarita[et al.] (British Pharmacological Society, 2017)
Background and purpose: Recombinant IFN-ß is one of the first-line treatments in multiple sclerosis (MS), despite its lack of efficacy in some patients. In this context, mesenchymal stem cells (MSCs) represent a promising ... -
Recombinant soluble IFN receptor (sIFNAR2) exhibits intrinsic therapeutic efficacy in a murine model of Multiple Sclerosis
Suardíaz García, Margarita; Clemente, Diego; Marín Bañasco, Carmen; Órpez, Teresa; Hurtado-Guerrero, Isaac; Pavía-Molina, José; Pinto-Medel, Maria Jesús; De Castro, Fernando; Leyva-Fernández, Laura; Fernández Fernández, Óscar; Oliver-Martos, Begoña[et al.] (Elsevier, 2016)
Endogenous interferon beta (IFNβ) is an important cytokine involved in several chronic inflammatory diseases, such as Multiple Sclerosis (MS). In spite of the numerous therapeutic approaches available for MS patients, the ... -
TRAIL and TRAIL receptors splice variants during long-term interferon β treatment of patients with multiple sclerosis: evaluation as biomarkers for therapeutic response
López-Gómez, Carlos; Oliver-Martos, Begoña; Pinto-Medel, María Jesús; Suardíaz García, Margarita; Reyes-Garrido, Virginia; Urbaneja, Patricia; Fernández-Fernández, Óscar; Leyva-Fernández, Laura[et al.] (BMJ Journals, 2016)
Objective We aimed to assess the effects of interferon β (IFNβ) treatment on the expression of the splice variants of the Tumour necrosis factor-Related Apoptosis Inducing Ligand (TRAIL) and its receptors in different cell ...